Cytokine-targeted therapies for asthma and COPD.


Journal

European respiratory review : an official journal of the European Respiratory Society
ISSN: 1600-0617
Titre abrégé: Eur Respir Rev
Pays: England
ID NLM: 9111391

Informations de publication

Date de publication:
30 Jun 2023
Historique:
received: 12 10 2022
accepted: 23 01 2023
medline: 21 4 2023
pubmed: 20 4 2023
entrez: 19 04 2023
Statut: epublish

Résumé

Asthma affects over 300 million people worldwide and its prevalence is increasing. COPD is the third leading cause of death globally. Asthma and COPD are complex inflammatory diseases of the airways in which impaired host defences lead to increased susceptibility to pathogens, pollutants and allergens. There is a constant interplay between host and the environment. Environmental exposures can alter the lung microbiome and influence the development of sensitisation by disrupting normal immunoregulation. The underlying airway inflammation in severe asthma is heterogeneous, with upregulation of type 2 cytokines in most cases but increased neutrophilic inflammation and activated T-helper 17 mediated immunity in others. COPD may also comprise several different phentoypes that are driven by different molecular mechanisms or endotypes. This disease heterogeneity is affected by comorbidities, treatments and environmental exposures. Recent intervention trials have shed light on the pathways beyond type 2 inflammation that can lead to beneficial outcomes

Identifiants

pubmed: 37076177
pii: 32/168/220193
doi: 10.1183/16000617.0193-2022
pmc: PMC10113955
pii:
doi:

Substances chimiques

Cytokines 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©The authors 2023.

Déclaration de conflit d'intérêts

Conflict of interest: F. Schleich has received grants or contracts from GSK, AstraZeneca and Chiesi; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, AstraZeneca, Chiesi and TEVA; and has participated on a Data Safety Monitoring Board or Advisory Board for GSK and AstraZeneca. Conflict of interest: N. Bougard has nothing to disclose. Conflict of interest: C. Moermans has nothing to disclose. Conflict of interest: M. Sabbe has nothing to disclose. Conflict of interest: R. Louis has received grants or contracts from GSK, AstraZeneca and Chiesi; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, AstraZeneca, Chiesi and TEVA; and has participated on a Data Safety Monitoring Board or Advisory Board for GSK and AstraZeneca.

Références

Lancet Respir Med. 2016 Oct;4(10):797-806
pubmed: 27574788
Am J Respir Crit Care Med. 2012 Feb 1;185(3):267-74
pubmed: 22108207
Eur Respir J. 2017 Sep 11;50(3):
pubmed: 28893867
Am J Respir Crit Care Med. 2019 Aug 1;200(3):309-317
pubmed: 30875247
Thorax. 2018 Aug;73(8):782-784
pubmed: 29079610
Chest. 2011 Jan;139(1):165-73
pubmed: 21208876
Ther Adv Chronic Dis. 2021 Jul 07;12:20406223211028768
pubmed: 34285789
Respir Med. 2013 Oct;107(10):1521-30
pubmed: 23993706
BMC Pulm Med. 2013 Feb 26;13:11
pubmed: 23442497
N Engl J Med. 2017 Jun 22;376(25):2448-2458
pubmed: 28530840
Am J Respir Crit Care Med. 2013 Dec 1;188(11):1294-302
pubmed: 24200404
J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2412-2413.e2
pubmed: 32268213
Am J Respir Crit Care Med. 2011 Nov 15;184(10):1125-32
pubmed: 21852542
Ann Intern Med. 2011 May 3;154(9):573-82
pubmed: 21536936
N Engl J Med. 2019 Sep 12;381(11):1023-1034
pubmed: 31112385
Lancet Respir Med. 2015 Jun;3(6):435-42
pubmed: 25878028
Chest. 2022 Jul;162(1):46-55
pubmed: 35217003
Int Arch Allergy Immunol. 2018;176(3-4):225-233
pubmed: 29772578
Lancet Respir Med. 2017 May;5(5):390-400
pubmed: 28395936
Thorax. 2013 Apr;68(4):322-9
pubmed: 23291349
J Allergy Clin Immunol Pract. 2019 Jan;7(1):156-164.e1
pubmed: 29800752
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
Sci Immunol. 2021 Jan 29;6(55):
pubmed: 33514640
Eur Respir J. 2016 May;47(5):1562-4
pubmed: 26846827
Int Arch Allergy Immunol. 2021;182(4):311-318
pubmed: 33113532
Respir Res. 2020 Jan 3;21(1):3
pubmed: 31900184
Ann Allergy Asthma Immunol. 2021 Feb;126(2):187-193
pubmed: 33169672
Chest. 2021 Feb;159(2):496-506
pubmed: 32882249
Allergy. 2009 Jan;64(1):72-80
pubmed: 19076931
Respir Med. 2009 Nov;103(11):1633-42
pubmed: 19619998
Thorax. 2002 Oct;57(10):875-9
pubmed: 12324674
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1267-1275
pubmed: 33039645
Lancet Respir Med. 2021 Aug;9(8):873-884
pubmed: 33609487
J Allergy Clin Immunol. 2016 Jul;138(1):16-27
pubmed: 27373322
Lancet Respir Med. 2021 Nov;9(11):1288-1298
pubmed: 34302758
Lancet Respir Med. 2017 Dec;5(12):956-967
pubmed: 29146301
J Allergy Clin Immunol. 2019 Jul;144(1):1-12
pubmed: 31277742
Curr Med Res Opin. 2007 Oct;23(10):2379-86
pubmed: 17711616
N Engl J Med. 2014 Sep 25;371(13):1198-207
pubmed: 25199059
Lancet. 2014 Aug 23;384(9944):691-702
pubmed: 25152271
Lancet. 2006 Aug 26;368(9537):804-13
pubmed: 16935691
Lancet Respir Med. 2019 Oct;7(10):907-920
pubmed: 30975495
Respir Med. 2010 Oct;104(10):1410-6
pubmed: 20483574
Respir Med. 2014 Dec;108(12):1723-32
pubmed: 25456708
N Engl J Med. 2021 May 13;384(19):1800-1809
pubmed: 33979488
Adv Ther. 2022 May;39(5):2065-2084
pubmed: 35287231
Allergy. 2019 Jul;74(7):1249-1256
pubmed: 30834543
N Engl J Med. 2022 Jan 13;386(2):157-171
pubmed: 35020986
J Allergy Clin Immunol. 2021 Jan;147(1):158-167
pubmed: 32353489
Lancet Respir Med. 2014 Dec;2(12):988-96
pubmed: 25458200
Lung. 2020 Apr;198(2):355-360
pubmed: 32052155
Thorax. 2018 Apr;73(4):331-338
pubmed: 29269441
N Engl J Med. 2014 Sep 25;371(13):1189-97
pubmed: 25199060
Chest. 2016 Oct;150(4):799-810
pubmed: 27018175
Int J Chron Obstruct Pulmon Dis. 2021 Jun 16;16:1755-1770
pubmed: 34163157
J Allergy Clin Immunol. 2021 Sep;148(3):790-798
pubmed: 33872652
Lancet. 1999 Jun 26;353(9171):2213-4
pubmed: 10392993
N Engl J Med. 2018 Jun 28;378(26):2475-2485
pubmed: 29782224
Clin Exp Allergy. 2020 Jun;50(6):687-695
pubmed: 32198794
Eur Respir J. 2018 May 24;51(5):
pubmed: 29700102
Eur Respir J. 2020 Nov 12;56(5):
pubmed: 32586879
Lancet. 2017 Aug 12;390(10095):659-668
pubmed: 28687413
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
Lancet Respir Med. 2015 May;3(5):355-66
pubmed: 25736990
J Allergy Clin Immunol. 2007 May;119(5):1043-52; quiz 1053-4
pubmed: 17472810
Am J Respir Crit Care Med. 2013 Apr 15;187(8):804-11
pubmed: 23471469
Allergy. 2005 Mar;60(3):309-16
pubmed: 15679715
N Engl J Med. 2002 May 30;346(22):1699-705
pubmed: 12037149
Sci Transl Med. 2020 Aug 19;12(557):
pubmed: 32817367
Chest. 2023 Feb 3;:
pubmed: 36740095
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Respir Med. 2018 Aug;141:56-63
pubmed: 30053973
Eur Respir J. 2016 Feb;47(2):410-9
pubmed: 26828055
J Allergy Clin Immunol. 2013 Aug;132(2):485-6.e11
pubmed: 23591271
J Allergy Clin Immunol. 2018 Jun;141(6):2027-2036.e12
pubmed: 29709671
Lancet Respir Med. 2022 Jan;10(1):11-25
pubmed: 34597534
Eur Respir J. 2021 Oct 28;58(4):
pubmed: 34266940
Lancet. 2016 Oct 29;388(10056):2115-2127
pubmed: 27609408
Curr Opin Allergy Clin Immunol. 2019 Feb;19(1):53-60
pubmed: 30516548
Eur Respir J. 2018 May 10;51(5):
pubmed: 29545284
Lancet Respir Med. 2021 Mar;9(3):260-274
pubmed: 33357499
J Allergy Clin Immunol. 2022 May;149(5):1582-1584
pubmed: 35149043
N Engl J Med. 2021 Dec 9;385(24):2230-2240
pubmed: 34879449
J Allergy Clin Immunol Pract. 2013 Mar;1(2):163-71
pubmed: 24565455
Eur Respir J. 2019 Dec 4;54(6):
pubmed: 31467116
Arch Bronconeumol. 2022 Aug;58(8):583-585
pubmed: 35312613
Respir Res. 2017 Jul 3;18(1):133
pubmed: 28673351
N Engl J Med. 2011 Aug 25;365(8):689-98
pubmed: 21864166
Eur Respir J. 2014 Jul;44(1):97-108
pubmed: 24525441
J Allergy Clin Immunol Pract. 2021 Dec;9(12):4334-4342.e6
pubmed: 34358701
Thorax. 2012 Aug;67(8):665-7
pubmed: 22544895
Lancet Respir Med. 2014 Nov;2(11):891-901
pubmed: 25208464
Lancet. 2016 Oct 29;388(10056):2128-2141
pubmed: 27609406
Lancet Respir Med. 2016 Nov;4(11):911-924
pubmed: 27264777
N Engl J Med. 2017 Sep 7;377(10):936-946
pubmed: 28877011
Lancet Respir Med. 2021 Nov;9(11):1299-1312
pubmed: 34256031
Eur Respir J. 2020 Aug 20;56(2):
pubmed: 32430415
Eur Respir J. 2017 Oct 5;50(4):
pubmed: 28982774
Respir Med. 2010 Nov;104(11):1608-17
pubmed: 20801010
Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24
pubmed: 19815809
BMC Pulm Med. 2016 Apr 05;16:46
pubmed: 27044366
N Engl J Med. 2021 Oct 28;385(18):1669-1679
pubmed: 34706172
Thorax. 2007 Dec;62(12):1043-9
pubmed: 17356056
Allergy. 2004 Jul;59(7):709-17
pubmed: 15180757
N Engl J Med. 2017 May 18;376(20):1911-1920
pubmed: 28514613
N Engl J Med. 2017 Oct 26;377(17):1613-1629
pubmed: 28893134
J Allergy Clin Immunol. 2020 Mar;145(3):757-765
pubmed: 31866436
Eur Respir J. 2021 Jan 21;57(1):
pubmed: 32586877
Clin Exp Allergy. 2020 Jul;50(7):789-798
pubmed: 32469092
Chest. 2016 Oct;150(4):789-798
pubmed: 27056586
Biochem Pharmacol. 2020 Sep;179:113944
pubmed: 32240649
Am J Respir Crit Care Med. 2019 Aug 15;200(4):444-453
pubmed: 30973757
J Allergy Clin Immunol. 2021 Mar;147(3):827-844
pubmed: 33307116
Thorax. 2016 Feb;71(2):118-25
pubmed: 26585525
N Engl J Med. 2021 Oct 28;385(18):1656-1668
pubmed: 34706171
Lancet. 2002 Nov 30;360(9347):1715-21
pubmed: 12480423
Eur Respir J. 2020 Oct 15;56(4):
pubmed: 32817259
Lancet. 2016 Jul 2;388(10039):31-44
pubmed: 27130691
J Allergy Clin Immunol Pract. 2022 Jan;10(1):222-228
pubmed: 34419680

Auteurs

Florence Schleich (F)

Respiratory Medicine, CHU of Liege, Belgium fschleich@chuliege.be.
GIGA I3, University of Liege, Belgium.

Nicolas Bougard (N)

Respiratory Medicine, CHU of Liege, Belgium.

Catherine Moermans (C)

GIGA I3, University of Liege, Belgium.

Mare Sabbe (M)

Respiratory Medicine, CHU of Liege, Belgium.

Renaud Louis (R)

Respiratory Medicine, CHU of Liege, Belgium.
GIGA I3, University of Liege, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH